Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL
Abroad (travel likely)Active Not RecruitingPHASE2
Conditions
Hairy Cell Leukemia
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Study leads
Robert J Kreitman, M.D.
Principal Investigator
National Cancer Institute (NCI)
View source on ClinicalTrials.gov(opens in a new tab)
No study contact email or phone is listed for this trial.